Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis
Abstract Background For gastric cancer patients, peritoneal metastasis poses a life-threatening risk due to the high incidence of treatment failure and disease recurrence. Conducting additional research aimed at identifying more efficacious strategies is imperative for enhancing treatment outcomes....
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-14206-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849469878741762048 |
|---|---|
| author | Yuxi Ma Yuting Li Zhenyu Lin Jing Wang Jianli Hu Hongli Liu Yali Yang Junli Liu Tao Zhang |
| author_facet | Yuxi Ma Yuting Li Zhenyu Lin Jing Wang Jianli Hu Hongli Liu Yali Yang Junli Liu Tao Zhang |
| author_sort | Yuxi Ma |
| collection | DOAJ |
| description | Abstract Background For gastric cancer patients, peritoneal metastasis poses a life-threatening risk due to the high incidence of treatment failure and disease recurrence. Conducting additional research aimed at identifying more efficacious strategies is imperative for enhancing treatment outcomes. This study examined the efficacy and safety of systemic chemotherapy plus a PD-1 inhibitor combination with intravenous or intraperitoneal bevacizumab for gastric cancer with peritoneal metastasis. Methods We conducted the open label, two-arm pilot study involved receiving albumin-bound paclitaxel (260 mg/m2, d1) plus S-1 (80 mg/m2, d1-14) combined with sintilimab (200 mg, d1) and bevacizumab (7.5 mg/m2, d1) (Arm A) intraperitoneally for moderate or large ascites or intravenously (Arm B) for non- or small ascites. The clinical trial was registered at the Chinese Clinical Trial Registry (ChiCTR2100048947 DATE: 2021-07-19). Results Ten gastric cancer patients with peritoneal metastasis were enrolled in two arms (four in Arm A and six in Arm B) from August 19th, 2021 to June 1st, 2022. Until the end of the follow-up date, the mPFS for Arm A was 5.70 m (95% CI: 1.29–10.11), while Arm B had a mPFS of 9.07 m (95% CI: 3.79–14.35). The mOS for Arm A and Arm B was 8.43 (95% CI: 6.70-10.17) and 11.23 months (95% CI: 2.90-19.56). At least one common Grade 3/4 AE occurred in 25% of Arm A participants and 16.7% of Arm B patients. Conclusions Albumin-bound paclitaxel plus S-1 with a PD-1 inhibitor and intraperitoneal or intravenous bevacizumab was well tolerated in gastric cancer patients with peritoneal metastasis. |
| format | Article |
| id | doaj-art-aced03e826ff46d0bac757db0ffa0dc6 |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-aced03e826ff46d0bac757db0ffa0dc62025-08-20T03:25:19ZengBMCBMC Cancer1471-24072025-06-012511910.1186/s12885-025-14206-9Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasisYuxi Ma0Yuting Li1Zhenyu Lin2Jing Wang3Jianli Hu4Hongli Liu5Yali Yang6Junli Liu7Tao Zhang8Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAbstract Background For gastric cancer patients, peritoneal metastasis poses a life-threatening risk due to the high incidence of treatment failure and disease recurrence. Conducting additional research aimed at identifying more efficacious strategies is imperative for enhancing treatment outcomes. This study examined the efficacy and safety of systemic chemotherapy plus a PD-1 inhibitor combination with intravenous or intraperitoneal bevacizumab for gastric cancer with peritoneal metastasis. Methods We conducted the open label, two-arm pilot study involved receiving albumin-bound paclitaxel (260 mg/m2, d1) plus S-1 (80 mg/m2, d1-14) combined with sintilimab (200 mg, d1) and bevacizumab (7.5 mg/m2, d1) (Arm A) intraperitoneally for moderate or large ascites or intravenously (Arm B) for non- or small ascites. The clinical trial was registered at the Chinese Clinical Trial Registry (ChiCTR2100048947 DATE: 2021-07-19). Results Ten gastric cancer patients with peritoneal metastasis were enrolled in two arms (four in Arm A and six in Arm B) from August 19th, 2021 to June 1st, 2022. Until the end of the follow-up date, the mPFS for Arm A was 5.70 m (95% CI: 1.29–10.11), while Arm B had a mPFS of 9.07 m (95% CI: 3.79–14.35). The mOS for Arm A and Arm B was 8.43 (95% CI: 6.70-10.17) and 11.23 months (95% CI: 2.90-19.56). At least one common Grade 3/4 AE occurred in 25% of Arm A participants and 16.7% of Arm B patients. Conclusions Albumin-bound paclitaxel plus S-1 with a PD-1 inhibitor and intraperitoneal or intravenous bevacizumab was well tolerated in gastric cancer patients with peritoneal metastasis.https://doi.org/10.1186/s12885-025-14206-9Gastric cancerPeritoneal metastasisChemotherapySintilimabBevacizumab |
| spellingShingle | Yuxi Ma Yuting Li Zhenyu Lin Jing Wang Jianli Hu Hongli Liu Yali Yang Junli Liu Tao Zhang Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis BMC Cancer Gastric cancer Peritoneal metastasis Chemotherapy Sintilimab Bevacizumab |
| title | Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis |
| title_full | Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis |
| title_fullStr | Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis |
| title_full_unstemmed | Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis |
| title_short | Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis |
| title_sort | safety and efficacy of systemic chemotherapy plus pd 1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis |
| topic | Gastric cancer Peritoneal metastasis Chemotherapy Sintilimab Bevacizumab |
| url | https://doi.org/10.1186/s12885-025-14206-9 |
| work_keys_str_mv | AT yuxima safetyandefficacyofsystemicchemotherapypluspd1inhibitorincombinationwithintravenousorintraperitonealbevacizumabingastriccancerwithperitonealmetastasis AT yutingli safetyandefficacyofsystemicchemotherapypluspd1inhibitorincombinationwithintravenousorintraperitonealbevacizumabingastriccancerwithperitonealmetastasis AT zhenyulin safetyandefficacyofsystemicchemotherapypluspd1inhibitorincombinationwithintravenousorintraperitonealbevacizumabingastriccancerwithperitonealmetastasis AT jingwang safetyandefficacyofsystemicchemotherapypluspd1inhibitorincombinationwithintravenousorintraperitonealbevacizumabingastriccancerwithperitonealmetastasis AT jianlihu safetyandefficacyofsystemicchemotherapypluspd1inhibitorincombinationwithintravenousorintraperitonealbevacizumabingastriccancerwithperitonealmetastasis AT hongliliu safetyandefficacyofsystemicchemotherapypluspd1inhibitorincombinationwithintravenousorintraperitonealbevacizumabingastriccancerwithperitonealmetastasis AT yaliyang safetyandefficacyofsystemicchemotherapypluspd1inhibitorincombinationwithintravenousorintraperitonealbevacizumabingastriccancerwithperitonealmetastasis AT junliliu safetyandefficacyofsystemicchemotherapypluspd1inhibitorincombinationwithintravenousorintraperitonealbevacizumabingastriccancerwithperitonealmetastasis AT taozhang safetyandefficacyofsystemicchemotherapypluspd1inhibitorincombinationwithintravenousorintraperitonealbevacizumabingastriccancerwithperitonealmetastasis |